New Zealand's Rua Bioscience FY customer revenue jumps on Australia, NZ growth

Rua Bioscience

27/08/2026 22:08

Overview
New Zealand medicinal cannabis firm's preliminary FY26 customer revenue rose 71% yr/yr to NZ$2.58 mln
Preliminary FY26 pretax loss narrowed 3% to NZ$3.36 mln
Company secured largest export agreement to date, a UK deal expected to generate NZ$10 mln over two years

Outlook
Rua's sales and distribution agreement is expected to generate more than NZ$10 mln in revenue over its initial two-year term
Company aims for continued sales growth in New Zealand, Australia, Germany and the UK
Rua expects New Zealand sales revenue and margin to keep growing as its expanded product range reaches more patients

Result Drivers
INTERNATIONAL STRATEGY - Company said its export-led strategy expanded market access, while Australia and New Zealand primarily drove FY26 revenue growth
AUSTRALIA AND NEW ZEALAND GROWTH - Co said FY26 revenue growth was driven mainly by expansion in Australia and New Zealand
HIGHER FINANCE COSTS – Interest expense more than doubled to NZ$312,709 from NZ$145,916, limiting the reduction in loss before tax

Company press release: ID:nNZS9Fta

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
FY Revenue
 
NZ$2.92 mln
 
FY Pretax Loss
 
NZ$3.36 mln
 

Reuters Recommended Reads
Aug 27 - New Zealand's Comvita returns to profit on margin recovery, lower operating costs
Aug 26 - New Zealand's Me Today FY26 swings to profit on King Honey deconsolidation 
Aug 27 - China's CStone Pharmaceuticals H1 revenue soars on drug sales

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)